Market For Telemedicine And RPM Expanding, Says GlobalData

New Delhi (IANS) The market for telemedicine and remote patient monitoring (RPM) has been rapidly expanding, driven by the Covid-19 pandemic and the need for remote healthcare delivery, according to a report on Monday.

The report by GlobalData, a data and analytics company, stated that RPM devices are estimated to grow to a market value of $1.2 billion by 2025, while the market for telemedicine is projected to reach $185.6 billion by 2026.

RPM devices allow healthcare providers to monitor patients’ health metrics from a distance.

This technology provides early detection of health problems and can prevent unnecessary hospital visits, making it an attractive option for both patients and providers.

“Artificial Intelligence (AI) is also being integrated into telemedicine and RPM, enabling providers to analyse data from remote monitoring devices and gain valuable insights into patient health,” said Cynthia Stinchcombe, Medical Devices Analyst at GlobalData, in a statement.

Stinchcombe noted that the technology also has the potential to significantly improve patient outcomes as well as reduce healthcare costs.

In addition to these developments, telemedicine is also becoming more accessible to patients.

Virtual consultations allow patients to connect with their healthcare providers from anywhere, and market growth is being driven by the convenience and cost-effectiveness of virtual visits as well as the availability of high-speed internet and mobile devices.

“The expansion of telemedicine and RPM is expected to continue in the coming years, as these technologies become increasingly vital to the healthcare industry,” Stinchcombe said.

“With the ongoing Covid-19 pandemic and the growing demand for virtual healthcare, telemedicine and RPM are poised to play a critical role in delivering healthcare services to patients around the world,” she added.

  • Related Posts

    US FDA grants orphan drug designation for Lundbeck’s investigational anti-ACTH monoclonal antibody asedebart to treat endogenous Cushing’s syndrome

    Lundbeck, a biopharmaceutical company focusing exclusively on brain health, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to asedebart (Lu AG13909), Lundbeck’s novel…

    Fujifilm India installs Echelon Smart MRI at Jansons Health in Erode

    Fujifilm India, a leader in advanced diagnostic imaging and healthcare technology, has installed and commissioned the Fujifilm Echelon Smart MRI at Jansons Health in Erode. The installation expands access to…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    US FDA grants orphan drug designation for Lundbeck’s investigational anti-ACTH monoclonal antibody asedebart to treat endogenous Cushing’s syndrome

    US FDA grants orphan drug designation for Lundbeck’s investigational anti-ACTH monoclonal antibody asedebart to treat endogenous Cushing’s syndrome

    Fujifilm India installs Echelon Smart MRI at Jansons Health in Erode

    Fujifilm India installs Echelon Smart MRI at Jansons Health in Erode

    Rajasthan to prepare ‘Narcotics Control Vision 2026-29’ to curb drug abuse and trafficking

    Rajasthan to prepare ‘Narcotics Control Vision 2026-29’ to curb drug abuse and trafficking

    Bracco Imaging expands BubbleGen cell selection with CD3+ T Cell Isolation Kit

    Bracco Imaging expands BubbleGen cell selection with CD3+ T Cell Isolation Kit

    5 medicine samples found substandard in Bhiwadi warehouse raid; probe launched

    5 medicine samples found substandard in Bhiwadi warehouse raid; probe launched

    AiMeD welcomes govt’s offer supporting development of advanced testing infrastructure

    AiMeD welcomes govt’s offer supporting development of advanced testing infrastructure